Shares of Verastem Inc (NASDAQ:VSTM) have received a consensus recommendation of “Buy” from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.36.
A number of equities analysts have recently weighed in on VSTM shares. Oppenheimer restated a “buy” rating and issued a $15.00 target price on shares of Verastem in a research note on Sunday, December 10th. Cantor Fitzgerald set a $17.00 price objective on Verastem and gave the company a “buy” rating in a research note on Sunday, December 10th. Zacks Investment Research upgraded Verastem from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Cann reiterated a “buy” rating and issued a $13.00 price objective on shares of Verastem in a research note on Friday, January 26th. Finally, ValuEngine downgraded Verastem from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
A number of institutional investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in Verastem by 92.8% in the fourth quarter. Millennium Management LLC now owns 357,615 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 172,166 shares during the last quarter. Two Sigma Investments LP lifted its stake in Verastem by 133.7% in the fourth quarter. Two Sigma Investments LP now owns 261,771 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 149,744 shares during the last quarter. Two Sigma Advisers LP purchased a new position in Verastem in the fourth quarter valued at approximately $231,000. BVF Inc. IL purchased a new position in Verastem in the fourth quarter valued at approximately $6,908,000. Finally, Stonepine Capital Management LLC purchased a new position in Verastem in the fourth quarter valued at approximately $691,000. Institutional investors and hedge funds own 33.22% of the company’s stock.
Verastem (VSTM) opened at $3.26 on Wednesday. Verastem has a 12 month low of $1.14 and a 12 month high of $5.71. The firm has a market capitalization of $140.17, a P/E ratio of -1.99 and a beta of 2.24. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06.
COPYRIGHT VIOLATION NOTICE: “Verastem Inc (VSTM) Receives Consensus Recommendation of “Buy” from Analysts” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2018/03/14/verastem-inc-vstm-receives-consensus-recommendation-of-buy-from-analysts.html.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.